Ascendis Pharma (ASND) Misses Q1 EPS by 11c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR1.58), EUR0.11 worse than the analyst estimate of (EUR1.47). Revenue for the quarter came in at EUR100.95 million versus the consensus estimate of EUR93.49 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• Cytek faces $56M damages award in Beckman Coulter patent case
• Wolfe Research sees CNH stock flat 2027 outlook on commodity prices